Seattle Genetics Inc. (SGEN)
-NasdaqGS 36.70 
0.38(1.05%) May 17, 4:00PM EDT|After Hours
:
36.70 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 36.32 |
|---|
| Open: | 36.44 |
|---|
| Bid: | 18.44 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 32.42 |
|---|
| Beta: | 1.25 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 35.62 - 36.81 |
|---|
| 52wk Range: | 19.03 - 39.00 |
|---|
| Volume: | 418,957 |
|---|
| Avg Vol (3m): | 804,068 |
|---|
| Market Cap: | 4.42B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.49 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical CompaniesWall Street Transcript(Thu, May 16)
- SGEN's Adcetris under FDA ReviewZacks(Thu, May 16)
- SEATTLE GENETICS INC /WA FinancialsEDGAR Online Financials(Wed, May 15)
- Seattle Genetics' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Wed, May 15)
- FDA accepts Seattle Genetics Adcetris applicationAP(Tue, May 14)
- Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by the FDABusiness Wire(Tue, May 14)
- Companies Invest in Antibodies That Fight Tumorsat Motley Fool(Mon, May 13)
- These 4 Stocks Saw Trading Price Swings This Past Week Post Earningsat Wall St. Cheat Sheet(Sat, May 11)
- Seattle Genetics to Present at Upcoming Investor ConferencesBusiness Wire(Thu, May 9)
- The True Value Of Seattle Geneticsat Seeking Alpha(Thu, May 9)
- Narrower-than-Expected Loss at Seattle GeneticsZacks(Wed, May 8)
- SEATTLE GENETICS INC /WA Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Seattle Genetics Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Seattle Genetics Earnings: Here’s Why Shares are Up Nowat Wall St. Cheat Sheet(Tue, May 7)
- Seattle Genetics Earnings Call scheduled for 4:30 pm ET todayCCBN(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 19.90 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.82 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.19 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S.
View More